Axl expression represents an independent prognostic factor in cytogenetically normal de novo AML
| Variable . | OR (95% CI) . | P . |
|---|---|---|
| Axl expression below/above median | 5.46 (1.76-16.96) | .003 |
| Age | 0.97 (0.93-1.02) | .245 |
| Sex | 0.99 (0.33-2.95) | .986 |
| ECOG performance status | 0.66 (0.25-1.74) | .405 |
| Karyotype | – | All Cn AML |
| Cytogenetic risk group | – | All Cn AML |
| Leukocyte count | 1.00 (1.00-1.00) | .095 |
| Thrombocyte count | 1.00 (1.00-1.01) | .290 |
| Extramedullary disease | 3.42 (0.80-14.67) | .098 |
| Response to first induction therapy | 1.15 (0.37-3.62) | .808 |
| Blast count BM | 0.98 (0.96-1.00) | .055 |
| FLT3-ITD | 1.70 (0.58-5.00) | .336 |
| NRAS mutation | 0.36 (0.05-2.85) | .333 |
| IDH1/IDH2 | 1.42 (0.36-5.66) | .662 |
| WT1 mutation | 2.57 (0.71-9.26) | .1501 |
| WT1 SNP | 0.47 (0.15-1.48) | .198 |
| Variable . | OR (95% CI) . | P . |
|---|---|---|
| Axl expression below/above median | 5.46 (1.76-16.96) | .003 |
| Age | 0.97 (0.93-1.02) | .245 |
| Sex | 0.99 (0.33-2.95) | .986 |
| ECOG performance status | 0.66 (0.25-1.74) | .405 |
| Karyotype | – | All Cn AML |
| Cytogenetic risk group | – | All Cn AML |
| Leukocyte count | 1.00 (1.00-1.00) | .095 |
| Thrombocyte count | 1.00 (1.00-1.01) | .290 |
| Extramedullary disease | 3.42 (0.80-14.67) | .098 |
| Response to first induction therapy | 1.15 (0.37-3.62) | .808 |
| Blast count BM | 0.98 (0.96-1.00) | .055 |
| FLT3-ITD | 1.70 (0.58-5.00) | .336 |
| NRAS mutation | 0.36 (0.05-2.85) | .333 |
| IDH1/IDH2 | 1.42 (0.36-5.66) | .662 |
| WT1 mutation | 2.57 (0.71-9.26) | .1501 |
| WT1 SNP | 0.47 (0.15-1.48) | .198 |
Multivariate Cox regression survival analysis indicated that Axl represents an independent prognostic factor in Cn AML after correcting for established prognostic factors.